Bicycle Therapeutics (NASDAQ:BCYC) Sees Unusually-High Trading Volume

Bicycle Therapeutics plc (NASDAQ:BCYC) shares saw an uptick in trading volume on Wednesday . 431,556 shares were traded during trading, an increase of 13% from the previous session’s volume of 380,587 shares.The stock last traded at $22.52 and had previously closed at $22.68.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on BCYC shares. HC Wainwright cut their price target on shares of Bicycle Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, February 21st. Canaccord Genuity Group reissued a “buy” rating and set a $60.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, February 21st. Finally, Needham & Company LLC reissued a “buy” rating and set a $43.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $46.86.

Bicycle Therapeutics Stock Up 0.9 %

The company has a debt-to-equity ratio of 0.08, a current ratio of 8.08 and a quick ratio of 8.08. The firm’s 50 day moving average is $23.95 and its two-hundred day moving average is $19.34. The firm has a market capitalization of $682.81 million, a P/E ratio of -4.43 and a beta of 0.89.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Tuesday, February 20th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.07. Bicycle Therapeutics had a negative net margin of 669.72% and a negative return on equity of 57.80%. The business had revenue of $5.33 million during the quarter, compared to analysts’ expectations of $11.68 million. Research analysts predict that Bicycle Therapeutics plc will post -5.2 EPS for the current year.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,158 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $23.81, for a total transaction of $75,191.98. Following the completion of the sale, the chief executive officer now owns 387,270 shares of the company’s stock, valued at approximately $9,220,898.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 5,312 shares of company stock valued at $126,139 in the last quarter. 10.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Woodstock Corp lifted its holdings in shares of Bicycle Therapeutics by 4.5% during the fourth quarter. Woodstock Corp now owns 21,479 shares of the company’s stock worth $388,000 after buying an additional 926 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Bicycle Therapeutics during the third quarter worth $31,000. Exchange Traded Concepts LLC lifted its holdings in shares of Bicycle Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company’s stock worth $122,000 after buying an additional 1,706 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of Bicycle Therapeutics by 15.0% during the third quarter. Harbor Capital Advisors Inc. now owns 24,210 shares of the company’s stock worth $486,000 after buying an additional 3,165 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Bicycle Therapeutics by 489.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,001 shares of the company’s stock worth $72,000 after buying an additional 3,322 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.